CMP-001 in Combination With Pembrolizumab in Subjects With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Clinical trial NCT04633278 · TERMINATED

Trial details

NCT number: NCT04633278
Sponsor: Regeneron Pharmaceuticals
Status: TERMINATED
Phase: Phase 2
Study type: INTERVENTIONAL

Squamous Cell Carcinoma of Head and Neck

Start date: 2021-01-21
Primary completion: 2024-01-19
Enrollment: 24

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.